AI assistant
Sending…
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2011
Jul 6, 2011
30583_dirs_2011-07-06_ce23a64e-053e-4ca7-8053-c5fa612f3c6e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2011-07-01
Reporting Person: FUCHS HENRY J (EVP, Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-07-01 | Common Stock | M | 2500 | $11.05 | Acquired | 38955 | Direct |
| 2011-07-01 | Common Stock | S | 2500 | $27.68 | Disposed | 36455 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-07-01 | Stock Option (right to buy) | $11.05 | M | 2500 | Disposed | 2019-03-01 | Common Stock (2500) | Direct |
Footnotes
F1: Transaction made pursuant to a Rule 10b5-1 Trading plan executed on March 9, 2011.
F2: The range of sales prices received was $27.15 to $27.85. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
F3: Original option grant vests 6/48ths on September 2, 2009 and 1/48th on the 2nd of each month thereafter.
More from BIOMARIN PHARMACEUTICAL INC
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 4
Interim / Quarterly Report
2026
May 5
Report Publication Announcement
2026
May 4
M&A Activity
2026
Apr 27
M&A Activity
2026
Apr 23
Annual Report
2026
Apr 21
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19